
Sialanar - European Medicines Agency (EMA)
Sialanar is a medicine for treating severe drooling of saliva in children and adolescents (aged 3 years and above) with conditions affecting the nervous system, such as cerebral palsy, …
Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Sialanar should be …
Sialanar 320 micrograms/ml Glycopyrronium (400 …
2023年1月23日 · Sialanar is indicated for the paediatric population only. The elderly have a longer elimination half-life and reduced medicinal product clearance as well as limited data to support …
Sialanar is used to treat excessive production of saliva (sialorrhoea) in children and adolescents aged 3 years and older. Sialorrhoea (drooling or excessive salivation) is a common symptom …
Prescribing Information - Sialanar
Indication: Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Dosage: Start …
Glycopyrronium bromide | Drugs | BNFC | NICE
Glycopyrronium bromide (Sialanar®) for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic …
Sialanar® (glycopyrronium bromide)
Sialanar® (400mcg/ml glycopyrronium bromide equivalent to 320mcg/ml glycopyrronium) is licensed for the symptomatic treatment of severe sialorrhoea in children and adolescents aged …
Product overview | Severe sialorrhoea (drooling) in children and …
2017年2月14日 · Each millilitre (ml) of Sialanar 320 micrograms/ml oral solution contains 400 micrograms glycopyrronium bromide. Glycopyrronium bromide 400 microgram/ml oral solution …
Dose Table - Sialanar
Sialanar ® is licensed for the symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders. 1 Adverse event …
Sialanar 320mcg/ml,1×250ml(glycopyrronium 格隆铵口服溶液)
抗毒蕈碱药是乙酰胆碱作用于副交感神经(节后胆碱能)神经支配的自主效应部位毒蕈碱受体的竞争性抑制剂。 它们还抑制平滑肌缺乏胆碱能神经支配的乙酰胆碱的作用。 对3岁及以上患有慢 …
- 某些结果已被删除